Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Typical programmed cell death (PCD) requires de novo macromolecular synthesis and shares common morphological changes referred to as apoptosis. To elucidate the molecular mechanism of apoptosis, we isolated cDNA clones that are induced in differentiated PC12 cells deprived of NGF by differential display method. Among such clones, homology searches revealed that the one clone encodes the rat TATA-binding-protein-associated factor TAFII31, a component of TFIID, and a
transcriptional coactivator
of the
p53 protein
. Northern analysis of various organs in human showed one band in heart, brain, skeletal muscle and pancreas, whose size is approximately 1.1 kb which identical to that of human TAFII31 mRNA, although the size of rat human TAFII31 mRNA is approximately 2.7 kb. The deduced amino acid sequence of the rat TAFII31 was 77% identical to that of the human TAFII31. Northern analysis of various organs in adult mice showed that expression levels of TAFII31 mRNA were strong in heart but weak in spleen, although this gene is ubiquitously expressed.
...
PMID:Rat TAFII31 gene is induced upon programmed cell death in differentiated PC12 cells deprived of NGF. 916 94
The adenovirus E1A and SV40 large-T-antigen oncoproteins bind to members of the p300/CBP
transcriptional coactivator
family. Binding of p300/CBP is implicated in the transforming mechanisms of E1A and T-antigen oncoproteins. A common region of the T antigen is critical for binding both p300/CBP and the tumour suppressor
p53
, suggesting a link between the functions of
p53
and p300. Here we report that p300/CBP binds to
p53
in the absence of viral oncoproteins, and that p300 and
p53
colocalize within the nucleus and coexist in a stable DNA-binding complex. Consistent with its ability to bind to p300, E1A disrupted functions mediated by
p53
. It reduced
p53
-mediated activation of the p21 and bax promoters, and suppressed
p53
-induced cell-cycle arrest and apoptosis. We conclude that members of the p300/CBP family are transcriptional adaptors for
p53
, modulating its checkpoint function in the G1 phase of the cell cycle and its induction of apoptosis. Disruption of p300/
p53
-dependent growth control may be part of the mechanism by which E1A induces cell transformation. These results help to explain how
p53
mediates growth and checkpoint control, and how members of the p300/CBP family affect progression from G1 to the S phase of the cell cycle.
...
PMID:Binding and modulation of p53 by p300/CBP coactivators. 919 65
The
p53 tumor suppressor
gene product interacts with the p300
transcriptional coactivator
that regulates the transactivation of
p53
-inducible genes. The adenovirus E1A protein has been shown to bind to p300 and inhibit its function. E1A inhibits
p53
transactivation and also promotes
p53
accumulation by a p300-dependent mechanism. Murine double minute 2 (Mdm2) is a transcriptional target of
p53
that binds to
p53
and inhibits its transcriptional activity. E1A inhibited mdm2 transactivation without affecting the expression of p21(WAF1) or Bax, which resulted in high levels of
p53
accumulation and apoptosis. Ectopic expression of p300 restored Mdm2 levels and inhibited
p53
-dependent apoptosis, as did ectopic expression of Mdm2. Thus, p300 is required for mdm2 induction by
p53
and the subsequent inhibition of
p53
stabilization. Inhibition of p300 by E1A results in stabilization of
p53
and causes apoptosis. Moreover, E1B 19K or Bcl-2 expression in E1A-transformed cells abrogated
p53
-dependent apoptosis by restoring mdm2 transactivation by
p53
. Hence, p300 regulation of mdm2 expression controls apoptotic activity of
p53
, and 19K or Bcl-2 bypass E1A inhibition of p300 transactivation of Mdm2.
...
PMID:Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function. 964 2
The proliferating cell nuclear antigen (PCNA) is a highly conserved cellular protein that functions both in DNA replication and in DNA repair. Exposure of a rat embryo fibroblast cell line (CREF cells) to gamma radiation induced simultaneous expression of PCNA with the
p53 tumor suppressor protein
and the cyclin-dependent kinase inhibitor p21(WAF1/Cip1). PCNA mRNA levels transiently increased in serum-starved cells exposed to ionizing radiation, an observation suggesting that the radiation-associated increase in PCNA expression could be dissociated from cell cycle progression. Irradiation of CREF cells activated a transiently expressed PCNA promoter chloramphenicol acetyltransferase construct through
p53
binding sequences via a mechanism blocked by a dominant negative mutant p53. Electrophoretic mobility shift assays with nuclear extracts prepared from irradiated CREF cells produced four
p53
-specific DNA-protein complexes with the PCNA
p53
binding site. Addition of monoclonal antibody PAb421 (p53-specific) or AC238 (specific to the
transcriptional coactivator
p300/CREB binding protein) to the mobility shift assay distinguished different forms of
p53
that changed in relative abundance with time after irradiation. These findings suggest a complex cellular response to DNA damage in which
p53
transiently activates expression of PCNA for the purpose of limited DNA repair. In a population of nongrowing cells with diminished PCNA levels, this pathway may be crucial to survival following DNA damage.
...
PMID:p53-mediated regulation of proliferating cell nuclear antigen expression in cells exposed to ionizing radiation. 985 27
Many cellular stimuli result in the induction of both the
tumor suppressor p53
and NF-kappaB. In contrast to activation of
p53
, which is associated with the induction of apoptosis, stimulation of NF-kappaB has been shown to promote resistance to programmed cell death. These observations suggest that a regulatory mechanism must exist to integrate these opposing outcomes and coordinate this critical cellular decision-making event. Here we show that both
p53
and NF-kappaB inhibit each other's ability to stimulate gene expression and that this process is controlled by the relative levels of each transcription factor. Expression of either wild-type
p53
or the RelA(p65) NF-kappaB subunit suppresses stimulation of transcription by the other factor from a reporter plasmid in vivo. Moreover, endogenous, tumor necrosis factor alpha-activated NF-kappaB will inhibit endogenous wild-type
p53
transactivation. Following exposure to UV light, however, the converse is observed, with
p53
downregulating NF-kappaB-mediated transcriptional activation. Both
p53
and RelA(p65) interact with the
transcriptional coactivator
proteins p300 and CREB-binding protein (CBP), and we demonstrate that these results are consistent with competition for a limiting pool of p300/CBP complexes in vivo. These observations have many implications for regulation of the transcriptional decision-making mechanisms that govern cellular processes such as apoptosis. Furthermore, they suggest a previously unrealized mechanism through which dysregulated NF-kappaB can contribute to tumorigenesis and disease.
...
PMID:Transcriptional cross talk between NF-kappaB and p53. 1020 72
The transforming proteins of the small DNA tumor viruses, simian virus 40 (SV40), adenovirus, and human papillomavirus (HPV) target a number of identical cellular regulators whose functional abrogation is required for transformation. However, while both adenovirus E1A and SV40 large T transforming properties also depend on the targeting of the
transcriptional coactivator
CBP/p300, no such interaction has been described for the HPV oncoprotein E6 or E7. Here, we demonstrate that the HPV-16 E6 protein, previously shown to facilitate the degradation of
p53
in a complex with E6-associated protein (E6AP), also targets CBP/p300 in an interaction involving the C-terminal zinc finger of E6 and CBP residues 1808 to 1826. Furthermore, this interaction is limited to E6 proteins of high-risk HPVs associated with cervical cancer that have the capacity to repress
p53
-dependent transcription. An HPV-16 E6 mutant (L50G) that binds CBP/p300, but not E6AP, is still capable of down-regulating
p53
transcriptional activity. Thus, HPV E6 proteins possess two distinct mechanisms by which to abrogate
p53
function: the repression of
p53
transcriptional activity by targeting the
p53
coactivator CBP/p300, and the removal of cellular
p53 protein
through the proteosome degradation pathway.
...
PMID:The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. 1040 Jul 10
The E6 oncoprotein of bovine papillomavirus type 1 (BPV-1) can transform cells independently of
p53
degradation. The precise mechanisms underlying this transformation are not yet completely understood. Here it is shown that BPV-1 E6 interacts with CBP/p300 in the same way as described for the E6 proteins of oncogenic human papillomaviruses. This interaction results in an inhibition of the
transcriptional coactivator
function of CBP/p300 required by
p53
and probably by other transcription factors. The comparison of the CBP/p300-binding properties of BPV-1 E6 mutants previously characterized in transcription and transformation studies suggests (i) that the E6-CBP/p300 interaction may be necessary, but not sufficient, for cell transformation, and (ii) that the transcriptional activator function, inherent to the E6 protein, is not derived from forming a complex with CBP/p300.
...
PMID:Interaction with CBP/p300 enables the bovine papillomavirus type 1 E6 oncoprotein to downregulate CBP/p300-mediated transactivation by p53. 1103 72
The c-myb proto-oncogene product (c-Myb) is a sequence-specific DNA-binding protein that functions as a transcriptional activator. The
transcriptional coactivator
CREB-binding protein (CBP) binds via its KIX domain to the activation domain of c-Myb and mediates c-Myb-dependent transcriptional activation. CBP possesses intrinsic histone acetyltransferase activity, and can acetylate not only histones but also certain transcriptional factors such as GATA1 and
p53
. Here we demonstrate that the C/H2 domain of CBP, which is critical for the acetyltransferase activity, also directly interacts with the negative regulatory domain (NRD) of c-Myb. Consistent with this observation, CBP acetylated c-Myb in vitro at Lys(438) and Lys(441) within the NRD. In addition, CBP acetylated c-Myb in vivo not only at the sites found in this study but also at the p300-induced acetylation sites reported recently. Replacement of lysine by arginine at all of these sites dramatically decreased the trans-activating capacity of c-Myb. The results of transcriptional activation assays with c-Myb acetylation site mutants suggested that acetylation of c-Myb at each of these five sites synergistically enhances c-Myb activity. Mutations of these acetylation sites reduced the strength of the interaction between c-Myb and CBP. Thus, acetylation of c-Myb by CBP increases the trans-activating capacity of c-Myb by enhancing its association with CBP. These results demonstrate a novel molecular mechanism of regulation of c-Myb activity.
...
PMID:Increased affinity of c-Myb for CREB-binding protein (CBP) after CBP-induced acetylation. 1107 48
The non-structural protein NS1, encoded by the parvovirus minute virus of mice (MVM), is a potent regulator of viral gene expression in addition to prominent roles in viral replication and cytopathic effects associated with parvoviral infection. Although NS1 involves the modulation of viral and cellular transcription, the primary activation mechanism of MVM NS1 remains unclear. In the present study, we show here that the coactivator CREB binding protein, CBP, could potentiate NS1-mediated transcription as measured on the P38 promoter, which drives expression of the MVM capsid genes. NS1 bound to the two related cysteine-histidine-rich regions of CBP, referred to as C/H1 and C/H3, the former of which has an antagonistic function to CBP upon the NS1-transactivation. Furthermore, NS1 inhibited the synergistic transactivation by CBP and
p53
. These findings suggested that CBP as a
transcriptional coactivator
is required for NS1-mediated viral and cellular transcription in parvovirus-infected cells, resulting in cell proliferation and differentiation to achieve its lytic cycle.
...
PMID:Effects of interaction between parvovirus minute virus of mice NS1 and coactivator CBP on NS1- and p53-transactivation. 1111 8
p53 binding protein 1 (53BP1), a protein proposed to function as a
transcriptional coactivator
of the
p53 tumor suppressor
, has BRCT domains with high homology to the Saccharomyces cerevisiae Rad9p DNA damage checkpoint protein. To examine whether 53BP1 has a role in the cellular response to DNA damage, we probed its intracellular localization by immunofluorescence. In untreated primary cells and U2OS osteosarcoma cells, 53BP1 exhibited diffuse nuclear staining; whereas, within 5-15 min after exposure to ionizing radiation (IR), 53BP1 localized at discreet nuclear foci. We propose that these foci represent sites of processing of DNA double-strand breaks (DSBs), because they were induced by IR and chemicals that cause DSBs, but not by ultraviolet light; their peak number approximated the number of DSBs induced by IR and decreased over time with kinetics that parallel the rate of DNA repair; and they colocalized with IR-induced Mre11/NBS and gamma-H2AX foci, which have been previously shown to localize at sites of DSBs. Formation of 53BP1 foci after irradiation was not dependent on ataxia-telangiectasia mutated (ATM), Nijmegen breakage syndrome (NBS1), or wild-type
p53
. Thus, the fast kinetics of 53BP1 focus formation after irradiation and the lack of dependency on ATM and NBS1 suggest that 53BP1 functions early in the cellular response to DNA DSBs.
...
PMID:p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. 1113 68
1
2
3
4
5
6
7
8
Next >>